Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity

Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 2016-02, Vol.137 (2), p.e20152005-e20152005
Main Authors: Wu, Lu-Hsuan, Yang, Yea-Huei Kao, Lin, Chyi-Her, Lin, Yuh-Jyh, Cheng, Ching-Lan
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Bevacizumab
Bevacizumab - adverse effects
Bevacizumab - therapeutic use
Care and treatment
Diseases in Twins - drug therapy
Drug Administration Schedule
Drug therapy
Eye diseases
Female
Health aspects
Humans
Hypotension
Hypotension - chemically induced
Hypotension - diagnosis
Infant, Newborn
Infant, Premature
Infants (Premature)
Influence
Intravitreal Injections
Male
Monoclonal antibodies
Pediatrics
Premature birth
Premature infants
Retinopathy of prematurity
Retinopathy of Prematurity - drug therapy
Retrolental fibroplasia
Side effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravitreal bevacizumab therapy in preterm infants for retinopathy of prematurity (ROP) can be associated with hypotension. We report twin preterm infants who developed hypotension within 1 day after intravitreal bevacizumab therapy for ROP. Before receiving the medication, their clinical statuses were stable and similar. The dose, procedure, and premedication were the same; however, twin B presented with hypotension for 3 days. Although bevacizumab-related hypotension has been described in product information (incidence rate 7%-15%), this is the first case report of intravitreal bevacizumab for ROP inducing hypotension. Physicians should be aware of intravitreal bevacizumab therapy-related hypotension when treating ROP. We suggest conducting a postmarketing active surveillance on the systemic adverse effects of this regimen in preterm infants.
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.2015-2005